These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 29228728)
1. Protein tyrosine phosphatase receptor-type δ acts as a negative regulator suppressing breast cancer. Yu X; Zhang F; Mao J; Lu Y; Li J; Ma W; Fan S; Zhang C; Li Q; Wang B; Song B; Li L Oncotarget; 2017 Nov; 8(58):98798-98811. PubMed ID: 29228728 [TBL] [Abstract][Full Text] [Related]
2. IL-6 induces tumor suppressor protein tyrosine phosphatase receptor type D by inhibiting miR-34a to prevent IL-6 signaling overactivation. Zhang F; Wang B; Qin T; Wang L; Zhang Q; Lu Y; Song B; Yu X; Li L Mol Cell Biochem; 2020 Oct; 473(1-2):1-13. PubMed ID: 32602014 [TBL] [Abstract][Full Text] [Related]
3. Loss of Tyrosine Phosphatase Delta Promotes Gastric Cancer Progression via Signal Transducer and Activator of Transcription 3 Pathways. Wu L; Gao L; Kong D; Xue H Dig Dis Sci; 2019 Nov; 64(11):3164-3172. PubMed ID: 31041642 [TBL] [Abstract][Full Text] [Related]
4. Coexpression of gene Oct4 and Nanog initiates stem cell characteristics in hepatocellular carcinoma and promotes epithelial-mesenchymal transition through activation of Stat3/Snail signaling. Yin X; Zhang BH; Zheng SS; Gao DM; Qiu SJ; Wu WZ; Ren ZG J Hematol Oncol; 2015 Mar; 8():23. PubMed ID: 25879771 [TBL] [Abstract][Full Text] [Related]
5. A novel oncogenic role of inositol phosphatase SHIP2 in ER-negative breast cancer stem cells: involvement of JNK/vimentin activation. Fu CH; Lin RJ; Yu J; Chang WW; Liao GS; Chang WY; Tseng LM; Tsai YF; Yu JC; Yu AL Stem Cells; 2014 Aug; 32(8):2048-60. PubMed ID: 24802135 [TBL] [Abstract][Full Text] [Related]
6. Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells. Somasundaram V; Hemalatha SK; Pal K; Sinha S; Nair AS; Mukhopadhyay D; Srinivas P BMC Cancer; 2016 May; 16():336. PubMed ID: 27229859 [TBL] [Abstract][Full Text] [Related]
7. Twist2 contributes to breast cancer progression by promoting an epithelial-mesenchymal transition and cancer stem-like cell self-renewal. Fang X; Cai Y; Liu J; Wang Z; Wu Q; Zhang Z; Yang CJ; Yuan L; Ouyang G Oncogene; 2011 Nov; 30(47):4707-20. PubMed ID: 21602879 [TBL] [Abstract][Full Text] [Related]
8. PTPRD-inactivation-induced CXCL8 promotes angiogenesis and metastasis in gastric cancer and is inhibited by metformin. Bae WJ; Ahn JM; Byeon HE; Kim S; Lee D J Exp Clin Cancer Res; 2019 Dec; 38(1):484. PubMed ID: 31805999 [TBL] [Abstract][Full Text] [Related]
10. SHP-1 is a negative regulator of epithelial-mesenchymal transition in hepatocellular carcinoma. Fan LC; Shiau CW; Tai WT; Hung MH; Chu PY; Hsieh FS; Lin H; Yu HC; Chen KF Oncogene; 2015 Oct; 34(41):5252-63. PubMed ID: 25619838 [TBL] [Abstract][Full Text] [Related]
11. Notch1 induces epithelial-mesenchymal transition and the cancer stem cell phenotype in breast cancer cells and STAT3 plays a key role. Zhang X; Zhao X; Shao S; Zuo X; Ning Q; Luo M; Gu S; Zhao X Int J Oncol; 2015 Mar; 46(3):1141-8. PubMed ID: 25544568 [TBL] [Abstract][Full Text] [Related]
12. Protein tyrosine phosphatase receptor type delta (PTPRD) suppresses the expression of PD-L1 in human hepatocellular carcinoma by down-regulating STAT3. Meng Q; Tian J; Qin F; Huang X; Zhu D; Xiang B; Dong M Transl Cancer Res; 2020 Sep; 9(9):5574-5584. PubMed ID: 35117921 [TBL] [Abstract][Full Text] [Related]
13. Shp2 Plays a Critical Role in IL-6-Induced EMT in Breast Cancer Cells. Sun X; Zhang J; Wang Z; Ji W; Tian R; Zhang F; Niu R Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208810 [TBL] [Abstract][Full Text] [Related]
14. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Veeriah S; Brennan C; Meng S; Singh B; Fagin JA; Solit DB; Paty PB; Rohle D; Vivanco I; Chmielecki J; Pao W; Ladanyi M; Gerald WL; Liau L; Cloughesy TC; Mischel PS; Sander C; Taylor B; Schultz N; Major J; Heguy A; Fang F; Mellinghoff IK; Chan TA Proc Natl Acad Sci U S A; 2009 Jun; 106(23):9435-40. PubMed ID: 19478061 [TBL] [Abstract][Full Text] [Related]
15. Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells. Badache A; Hynes NE Cancer Res; 2001 Jan; 61(1):383-91. PubMed ID: 11196191 [TBL] [Abstract][Full Text] [Related]
16. Interleukin-6-induced epithelial-mesenchymal transition through signal transducer and activator of transcription 3 in human cervical carcinoma. Miao JW; Liu LJ; Huang J Int J Oncol; 2014 Jul; 45(1):165-76. PubMed ID: 24806843 [TBL] [Abstract][Full Text] [Related]
17. Tyrosine phosphatase PTPRD suppresses colon cancer cell migration in coordination with CD44. Funato K; Yamazumi Y; Oda T; Akiyama T Exp Ther Med; 2011 May; 2(3):457-463. PubMed ID: 22977525 [TBL] [Abstract][Full Text] [Related]
18. Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell-like differentiation in breast cancer. West NR; Murray JI; Watson PH Oncogene; 2014 Mar; 33(12):1485-94. PubMed ID: 23584474 [TBL] [Abstract][Full Text] [Related]
19. Upregulation of MEK5 by Stat3 promotes breast cancer cell invasion and metastasis. Liu F; Zhang H; Song H Oncol Rep; 2017 Jan; 37(1):83-90. PubMed ID: 27878304 [TBL] [Abstract][Full Text] [Related]
20. Aberrantly expressed Fra-1 by IL-6/STAT3 transactivation promotes colorectal cancer aggressiveness through epithelial-mesenchymal transition. Liu H; Ren G; Wang T; Chen Y; Gong C; Bai Y; Wang B; Qi H; Shen J; Zhu L; Qian C; Lai M; Shao J Carcinogenesis; 2015 Apr; 36(4):459-68. PubMed ID: 25750173 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]